The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The importance of the multidisciplinary team in the successful deployment of CAR-T therapies
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, emphasizes the critical role of a multidisciplinary team in the successful deployment of CAR-T therapies. He highlights the importance of teamwork within and outside the institution to ensure seamless patient care, rapid response to complications, and effective follow-up. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CAR-T treatment is teamwork. First of all, it’s teamwork within the region or within the country just to align the selection criteria for patients. But of course, it’s as much teamwork within your institution because although we get more and more experienced in giving CAR-T treatment, you want to make sure that the flow is easy for patients and of course also that in case there are complications, patients can be rapidly seen, for instance, by the neurologist, that your nurses are well trained, that you use the right tools to detect early signs of CRS...
CAR-T treatment is teamwork. First of all, it’s teamwork within the region or within the country just to align the selection criteria for patients. But of course, it’s as much teamwork within your institution because although we get more and more experienced in giving CAR-T treatment, you want to make sure that the flow is easy for patients and of course also that in case there are complications, patients can be rapidly seen, for instance, by the neurologist, that your nurses are well trained, that you use the right tools to detect early signs of CRS. And then when patients go home, that there is also a good follow-up that could be at your own institution, but also at the institute of the referring physician where everybody is well aware of what should be screened for and when there should be contact with the referring physician in case of any question or any adverse event.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen, BMS, GSJ, Janssen, Sanofi, Pfizer, Roche: Honoraria; Amgen, BMS, GSJ, Janssen, Sanofi, Pfizer, F. Hoffmann-La Roche Ltd: Consultancy; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Roche: Consultancy, Honoraria; University Hospital Leuven: Consultancy, Honoraria.
